SYBX (Synlogic) Utang jangka cendhak marang modal

This daily price chart for Synlogic, Inc. (SYBX) on the GURU.Markets platform shows the metric at 0.00. Synlogic, Inc. (SYBX) develops synthetic treatments for metabolic pathologies, mitigating risks through alliances with industry behemoths. The business targets patients with rare diagnoses, relying on insurance reimbursement for costs. Following a rigorous reorganization, the firm seeks a strategic partner to maintain liquidity and ensure survival.

For Synlogic, Inc., which develops biologics through strategic alliances, the short-term debt-to-equity ratio on GURU.Markets reflects the balance between operational autonomy and credit burden. The ratio of liabilities with a maturity of up to one year to shareholders' equity determines the business's degree of dependence on external financing, where low values confirm liquidity but may signal a conservative approach to scaling R&D projects.